Dualsteric and dual‐acting modulation of muscarinic receptors by antagonist KH‐5
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70570 ↗At a glance
Journal article in British Journal of Pharmacology, 2026. Written by Alena Janoušková-Randáková and 3 co-authors. Institution: Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. Major MEDLINE topics: Muscarinic Antagonists, Receptor, Muscarinic M1, Receptor, Muscarinic M2. 64 references. The full text is freely available (open access, CC BY 4.0). Funded by: Czech Academy of Sciences, Grant Agency of the Czech Republic, Akademie Věd České Republiky.
Abstract (original language)
Background and purpose Muscarinic acetylcholine receptors are key therapeutic targets, and ligands engaging both orthosteric and allosteric sites may offer improved selectivity and efficacy. Here, we investigated whether the muscarinic antagonist KH‐5 acts as a dualsteric antagonist and defined its mode of interaction with muscarinic receptors. Experimental approach Functional responses at human M 1 and M 2 receptors expressed in CHO cells were assessed using inositol phosphate accumulation and [ 35 S]GTP γ S binding, respectively. Radioligand binding studies employed orthosteric antagonists and agonists in combination with KH‐5 and classical allosteric modulators. Data were analysed using competitive, allosteric and dualsteric binding and operational models. Molecular docking, molecular dynamics simulations, and site‐directed mutagenesis were used to identify structural determinants of KH‐5 binding. Key results KH‐5 antagonised responses to multiple agonists in a saturable and probe‐dependent manner, but did not decrease maximal response to agonists, contradicting simple allosteric antagonism. At M 2 receptors, antagonism was largely competitive. Binding studies revealed transient enhancement of agonist binding at M 1 receptors at nanomolar concentrations of KH‐5, best described by a dualsteric binding model involving independent orthosteric and ectopic site interactions. KH‐5 did not bind to the classical muscarinic allosteric site at the second extracellular loop but interacted with an extracellular vestibule site. Conclusions and implications At M 1 receptors, the most parsimonious model among those tested combines orthosteric competition with an ectopic/allosteric component. At M 2 receptors, KH‐5 behaves predominantly as an orthosteric antagonist under the present conditions, although a weak or probe‐specific allosteric component cannot be excluded.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic.
ORCID profiles: Alena Janoušková-Randáková, Eva Dolejší, Nikolai Chetverikov, Jan Jakubík
Funding
- Czech Academy of Sciences
- Grant Agency of the Czech Republic
- Akademie Věd České Republiky
- Grantová Agentura České Republiky
Cite
APA
Janoušková-Randáková, A., Dolejší, E., Chetverikov, N., & Jakubík, J. (2026). Dualsteric and dual‐acting modulation of muscarinic receptors by antagonist KH‐5. British Journal of Pharmacology. https://doi.org/10.1111/bph.70570
Vancouver
Janoušková-Randáková A, Dolejší E, Chetverikov N, Jakubík J. Dualsteric and dual‐acting modulation of muscarinic receptors by antagonist KH‐5. British Journal of Pharmacology. 2026. doi:10.1111/bph.70570
BibTeX
@article{JanoukovRandkov2026,
author = {Janoušková-Randáková, Alena and Dolejší, Eva and Chetverikov, Nikolai and Jakubík, Jan},
title = {Dualsteric and dual‐acting modulation of muscarinic receptors by antagonist KH‐5},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70570}
}
EUVIMED